| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Vantictumab | OMP-18R5; anti-Fzd7 | Phase 1 Clinical | Oncomed Pharmaceuticals Inc, Bayer AG | Solid tumours; Pancreatic Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |




